Low Dose Naltrexone (LDN): Uses, Benefits, and What to Expect

Short answer: LDN (typically 1–5 mg/day) has a distinct mechanism from standard-dose naltrexone and a favorable safety profile — but fibromyalgia evidence has weakened as trials got larger. The 2026 INNOVA 12-month RCT found no benefit over placebo, challenging the smaller early studies that built LDN's reputation.

Low dose naltrexone has built a devoted following in the chronic pain and autoimmune communities, particularly for fibromyalgia. It's a genuinely interesting drug with a real, distinct mechanism from its standard-dose use — but the clinical trial evidence has gotten notably weaker as the studies have gotten larger and better designed, including a major 2026 trial that found no benefit over placebo at all.

What LDN Actually Is

Naltrexone is an opioid receptor antagonist first developed in 1963, historically used at standard doses of 50–100 mg to treat opioid and alcohol dependence by blocking the euphoric effects of opioids at the mu-opioid receptor.^[1]

At much lower doses — typically 1 to 5 mg per day — naltrexone exhibits a genuinely different, almost paradoxical pharmacological profile, which is the entire basis for its use as "low dose naltrexone." Rather than producing sustained opioid receptor blockade, low-dose naltrexone causes only brief, transient blockade, which is thought to upregulate the body's own endogenous opioid (endorphin) signaling rather than suppress it.^[1]

LDN's second proposed mechanism is separate from opioid receptors entirely: it binds to Toll-like receptor 4 (TLR4) on microglia — the immune cells of the central nervous system — acting as an antagonist that dampens pro-inflammatory cytokine production and shifts activated, inflammatory microglia toward a quieter state.^[2] This anti-inflammatory mechanism has no equivalent at standard naltrexone doses, which work purely through classic opioid receptor blockade and have no established anti-inflammatory role.^[2]

What LDN Has Been Studied For

Based on the available — mostly small — clinical literature, LDN has been studied for fibromyalgia, multiple sclerosis, Crohn's disease, complex regional pain syndrome, and other centralized, non-cancer chronic pain syndromes. The evidence base is most developed for fibromyalgia specifically, where multiple randomized, double-blind, placebo-controlled trials have now been conducted — with genuinely mixed results.

The Fibromyalgia Evidence: How Bigger Trials Changed the Picture

This is worth walking through in order, because the trajectory of the evidence matters as much as any single result.

An early 2013 crossover trial of 31 women with fibromyalgia found LDN (4.5 mg) produced a significantly greater reduction in self-reported pain than placebo (28.8% vs. 18.0%), along with improved mood and life satisfaction — though not improved fatigue or sleep.^[3] This is the study most often cited in LDN marketing.

A larger 2024 randomized, double-blind, placebo-controlled trial of 99 women in Denmark, testing a similar low dose (6 mg) over 12 weeks, found no statistically significant difference in pain reduction between LDN and placebo — though it did note a possible signal for LDN improving fibromyalgia-related memory problems that the authors flagged as worth further study.^[4]

Then came the most rigorous test yet: the INNOVA study, a 12-month, single-center, randomized, double-blind, placebo-controlled trial — the longest LDN fibromyalgia trial conducted to date, with 98 women randomized to LDN 4.5 mg (n=48) or placebo (n=50). Presented at the EULAR 2026 Annual Meeting and published in European Journal of Pain, it found LDN failed to outperform placebo on pain or secondary outcomes at either the 3-month or 12-month mark.^[5]

A separate 2024 systematic review and meta-analysis pooling 4 randomized controlled trials (222 total fibromyalgia patients) did find a statistically significant reduction in pooled pain scores and improved pressure pain threshold with LDN versus placebo — though it also noted a higher incidence of vivid dreams and nausea with LDN.^[6]That review predates the INNOVA results, so it doesn't yet reflect the largest and longest trial's negative finding.

What This Trajectory Actually Means

Taken together, current evidence quality for LDN in fibromyalgia is best described as early and inconsistent, trending weaker as trial quality improves — not established. Small early trials suggested benefit; the largest, longest, most rigorous trial to date found none. That's a meaningful pattern, not just "mixed results" in the abstract.

Safety Profile

Across the fibromyalgia trials, LDN has consistently shown a favorable safety profile — adverse event rates similar to placebo, with no serious treatment-related adverse events reported. The most common side effects across studies are vivid dreams, nausea, and initial sleep disturbance.

Is LDN FDA-Approved?

LDN carries no FDA approval for fibromyalgia, multiple sclerosis, Crohn's disease, or any anti-inflammatory or immune-modulating use. It's used entirely off-label for these purposes, and since commercial naltrexone tablets are only manufactured at standard 50 mg strength, LDN is typically obtained exclusively through compounding pharmacies rather than as a standard retail prescription.

Comparing providers? SeeLDN pricing across Longevity providerson RENVA's Longevity hub.

The Bottom Line

LDN has a genuinely interesting and mechanistically distinct rationale compared to standard-dose naltrexone, and its safety profile across trials has been consistently favorable. But if you're considering it specifically for fibromyalgia, it's worth knowing the evidence trend clearly: the largest, longest, and most rigorously designed trial to date — published in 2026 — found no benefit over placebo, directly contradicting the smaller studies that built LDN's reputation in the first place.

Frequently Asked Questions